Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Am J Cardiol. 2021 Oct 27;162:80–85. doi: 10.1016/j.amjcard.2021.09.025

Table 7.

Univariate analysis of outcomes by direct oral anticoagulant type

Outcome Odds Ratio (95% CI) p-value
Dabigatran
Stroke/TIA*/Systemic embolism 0.72 (0.30 – 1.74) 0.47
Major Bleeding 0.56 (0.22 – 1.39) 0.21
Any Bleeding 1.03 (0.74 – 1.45) 0.85
Rivaroxaban
Stroke/TIA/Systemic embolism 0.87 (0.39 – 1.96) 0.74
Major Bleeding 0.41 (0.20 – 0.84) 0.14
Any Bleeding 0.67 (0.49 – 0.91) 0.01
Apixaban
Stroke/TIA/Systemic embolism 0.91 (0.46 – 1.77) 0.77
Major Bleeding 0.48 (0.24 – 0.95) 0.03
Any Bleeding 0.69 (0.50 – 0.95) 0.02
*

TIA – transient ischemic attack.